Gina Consylman joined bluebird bio in August 2021 as the Chief Financial Officer (CFO) of the Severe Genetic Disease Group, overseeing finance, tax, accounting, treasury, insurance and investor relations. She has more than 25 years of experience in finance, investor relations, strategy and business development. She joined Ironwood Pharmaceuticals in 2014 and served as SVP and CFO through July 2021. Prior to joining Ironwood, Gina served as Vice President, Corporate Controller and Principal Accounting Officer at Analogic Corporation, a publicly-held healthcare and security technology solutions company, where she oversaw the company’s global accounting and treasury teams. Prior to her work at Analogic, Gina served as Senior Director, Corporate Accounting at Biogen Inc., where she led the accounting teams for corporate and U.S. commercial business units. Gina also serves on the Board of Directors for Assembly Biosciences, Inc. Gina, a Certified Public Accountant, began her career in public accounting at Ernst & Young LLP. She holds a B.S. in accounting from Johnson & Wales University and a M.S. in taxation from Bentley University.